The relationship between brain-derived neurotrophic factor and metabolic syndrome in patients with chronic schizophrenia: A systematic review

• Published in: Neuropeptides (Edinburgh) Vol. 87; p. 102135
• Main Authors: Kalejahi, Parinaz, Kheirouri, Sorayya, Noorazar, Seyyed Gholamreza, Sanayei, Mahzad
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.06.2021; Elsevier Science Ltd
• Subjects: Antipsychotics; BDNF; Brain-derived neurotrophic factor; Clozapine; Gene polymorphism; Mental disorders; Metabolic syndrome; MetS; Schizophrenia; Statistical analysis; Systematic review; Schizophrenia; Brain-derived neurotrophic factor; MetS; Metabolic syndrome; BDNF
• ISSN: 0143-4179; 1532-2785
• DOI: 10.1016/j.npep.2021.102135

Schizophrenia is a serious long-term disorder in which the metabolic complications and abnormalities of the brain-derived neurotrophic factor (BDNF) can be found. In this study, we conducted a systematic review of the relationship between BDNF, metabolic syndrome (MetS) and its components in schizophrenic patients. Data were collected mainly from PubMed, Google Scholar, Scopus, and ProQuest databases. The keywords related to the BDNF, MetS, schizophrenia were searched. Two reviewers independently screened 1061 abstracts. And eventually, a total of 7 studies (6 observational and 1 interventional) was included in the systematic reviews. Four of the 7 study ascertained statistically significant inverse relationship between serum BDNF levels and MetS in schizophrenic patients. While in the other two studies, there was no inverse relationship. In the last selected study, the researchers found a weak association between the Val66Met polymorphism in BDNF Gene and clozapine-induced MetS. Although this relationship could not be determined but BDNF levels appear to be reduced in schizophrenic patients with MetS and factors such as sex and antipsychotic class differentiation, sampling and methodology and episodes of illness could play a role in the results and outcomes.